Abstract
Objective
To study adjunctive medications used with antipsychotic agents in schizophrenia via comparisons of antidepressant, anxiolytic and antiparkinsonian co‐prescribing.
Method
In the context of a national naturalistic prospective observational study, a database containing all the prescriptions from 100 French psychiatrists during the year 2002 was analysed. The inclusion criteria were a diagnosis of schizophrenia or schizoaffective disorder and age over 18. A log-linear model and generalised linear mixed models were used.
Results
In all 5,257 prescriptions for 922 patients were analysed. The proportion of patients who were prescribed an antiparkinsonian drug was 32.9%. Amisulpride, haloperidol, phenothiazines with a sedative action and depot typical antipsychotics proved more likely to be prescribed with antiparkinsonians. The frequency of antidepressant and anxiolytic prescriptions was 51.2% and 52.3%, respectively. Associations between atypical antipsychotics (except clozapine) and antidepressants were positive while associations between typical antipsychotics and antidepressants were not. There were no differences among antipsychotics for the prescription of anxiolytics.
Conclusions
Atypical antipsychotics can be expected to be less likely associated with antiparkinsonians. This result is indeed found for olanzapine, clozapine and to a limited extent for risperidone. Furthermore, a trend towards a positive association between atypical antipsychotics and antidepressants appears. In view of the antidepressive action of certain atypical antipsychotics, this result is surprising. The increase in the prescriptions of anxiolytics concerns all types of antipsychotics. In view of the increase in associated medications in schizophrenia and the difficulty of estimating it in randomised trials, this study underlines the contribution of naturalistic studies on this score.
Similar content being viewed by others
References
Clark EC, Stephen JB, Ellman TA, Peacock JP (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28:75–82
Magliano L, Fiorillo A, Guarneri M, Marasco C, De Rosa C, Malangone C, Maj M, The National Mental Health Project Working Group (2004) Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey. Eur J Clin Pharmacol 60:513–522
Brunot A, Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F, Cléry–Melin P, Herguetal T, Llorca PM, MoreauDefarges T, Guillon P, Lebrun T (2002) Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia (in French). Encephale 28:129–138
Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z (2002) Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 57:201–208
Frangou S, Lewis M (2000) Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 15:220–226
Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lepine JP (2000) Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 49:80–86
Frangou S, Lewis M (2000) Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 15:220–226
Ungvari GS, Chow LY, Chiu FK (1997) Modifying psychotropic drug prescription patterns: a follow-up survey. Psychiatry Clin Neurosci 51:309–314
Baldessarini RJ, Kando JC, Centorrino F (1995) Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry 152:1038–1044
Zito JM, Craig TJ, Wanderling J, Siegel C (1987) Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. Am J Psychiatry 144:778–782
ANAES (1994) Stratégies thérapteutiques à long terme dans les psychoses schizophréniques. Conférence de consensus Paris
Lader M (1999) Some adverse effects of antipsychotics: prevention and treatment. J Clin Psychiatry 12:39–42
Buchanan R, Kreyenbuhl A, Zito M, Lehman A (2002) Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 159:1035–1043
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychological Association, Washington
Agresti A (1990) Categorical data analysis. Wiley Interscience, New York
Stokes ME, Davis CS, Koch GG (2003) Categorial data analysis using the SAS system. Wiley Interscience, New York
Falissard B (1998) Comprendre et utiliser les statistiques dans les sciences de la vie. Masson, Paris
Littel RC, Milliken GA, Stroup WW (1998) SAS system for mixed models. SAS Institute, Cary, NC
Brown H, Prescott R (1999) Applied mixed models in medicine. Wiley Interscience, New York
Nicolas G, Duret M (1998) Rapport sur l'évaluation entre les besoins hospitaliers et les effectifs en anesthésie réanimation, gynécologie obstétrique, psychiatrie et radiologie
Gilbody S, Wahlbeck K, Adams C (2002) Randomised trials in schizophrenia: a critical perspective of the literature. Acta Psychiatr Scand 105:243–251
Whitehead C, Moss S, Cardno A, Lewis G (2002) Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev (2):CD002305
Wolkowitz O, Pickard D (1991) Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 148:714–726
Leucht S, Wahlbeck K, Hamann J, Kissing W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589
Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553–564
Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK (2000) Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord 2:196–199
Sajatovic M, Mullen JA, Sweitzer DE (2000) Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 63:1156–1163
Peuskens J, Moller HJ, Puech A (2002) Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 12:305–310
Parepally H, Chakravorty S, Levine J (2002) The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents. A naturalistic study at a state psychiatric hospital. Prog Neuropsychopharmacol Biol Psychiatry 26:437–440
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Acquaviva, E., Gasquet, I. & Falissard, B. Psychotropic combination in schizophrenia. Eur J Clin Pharmacol 61, 855–861 (2005). https://doi.org/10.1007/s00228-005-0034-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0034-6